Inclusion Criteria:
- Female patients, age 18~40
- Unilateral, operable, histologically confirmed adenocarcinoma of the breast
- Stage I-III
- Primary surgery with clear margins plus axillary dissection
- Able to start protocol Rx within 4 weeks of surgery
- HER-2 positive (IHC 3+ OR FISH+) and sequential use of trastuzumab followed by
chemotherapy
- Occult breast cancer with histologically confirmed primary invasive carcinoma or DICS
with microinvasion in the ipsilateral breast after surgery
- ECOG performance status 0-1
- Adequate cardiac, renal, hepatic and hematologic function
Exclusion Criteria:
- Metastatic disease
- Bilateral breast cancer (synchronous or metachronous)
- Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer
- Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or
cancer of the uterine cervix)
- HER-2 positive (IHC 3+ OR FISH+) and concurrence use of adjuvant chemotherapy and
trastuzumab
- Documented history of cardiac disease contradiction anthracyclines
- Concurrent serious illness
- Peripheral neuropathy of CTC grade>1
- History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated
castor oil), the vehicle used for commercial paclitaxel formulations
- Pregnancy or lactation